Michael A. Poss

TL;DR: Results suggest that compound 9, or derivatives thereof, has potential applications for the therapeutic lowering of atherogenic lipoprotein levels in humans.

TL;DR: A 2-pyridone ligand that binds to palladium and accelerates non-directed C–H functionalization with arene as the limiting reagent is reported, which is compatible with a broad range of aromatic substrates and demonstrated direct functionalization of advanced synthetic intermediates, drug molecules and natural products that cannot be used in excessive quantities.

TL;DR: In this article, the authors provided compounds which inhibit micromosal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and the compounds have the structure (1) or (2) wherein R1 to R6, Q, and X are as defined herein.

TL;DR: Optimization led to compounds such as water soluble 45, which possesses a favorable pharmacokinetic profile in mice and demonstrates significant antitumor activity in vivo in several murine and human models, including an engineered murine mammary tumor that overexpresses cyclin E, the coactivator of CDK2.

TL;DR: Novel compounds are provided which are inhibitors of MTP and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and have the structure (I) or I or I including pharmaceutically acceptable salts thereof or prodrug esters thereof, wherein q is 0, 1 or 2; Rx is H, alkyl, aryl or halogen; A is (1) a bond; (2) -O-; or (3) (i); B is: (ii) or (iii) or